Shortening Hepatitis C Treatment Feasible in Half of Patients
"New research suggests that hepatitis C virus (HCV) treatments can be shortened in half of patients receiving them without compromising efficacy, potentially leading to significant cost savings
.
An estimated 70 million individuals worldwide are chronically infected with HCV. Although the disease is curable, direct acting anti-viral (DAA) drugs used to treat HCV can be costly, ranging between $40,000 and $100,000. Despite advancements in treating HCV, cost and access remain a significant barrier for many patients
."